MBC Advocate· @MBCadvocate · X·· 1 day agoScore70
Body · original
Overall survival from the phase III postMONARCH trial of abemaciclib plus fulvestrant versus placebo plus fulvestrant for HR+, HER2- advanced breast cancer following progression on a prior CDK4/6 inhibitor plus endocrine therapy. $AZN $LLY #ESMO26 #BCAM https://www.annalsofoncology.org/article/S0923-7534%2826%2908075-0/fulltext
72 views · 0 likes · 0 reposts · 0 replies
Conference abstracts
1ROmatched by Rapid oral 1: Breast cancer, advanced stage
Overall survival from the phase 3 postMONARCH trial of abemaciclib + fulvestrant vs placebo + fulvestrant for HR+, HER2- advanced breast cancer following progression on a prior CDK4/6 inhibitor + endocrine therapy
https://esmocongress.esmo.orgSource: MBC Advocate · x.com